Evan S. Dellon, MD: A Daily Diary for Eosinophilic Esophagitis


PROSE allows patients to report their symptoms of dysphagia in real-time.

Patients with eosinophilic esophagitis (EoE) could struggle to realize the process they are making.

However, data presented at the 2021 American College of Gastroenterology (ACG) Annual Meeting, shows using a patient-reported daily diary called the Patient Reported Outcomes for the Symptoms of Eosinophilic Esophagitis (PROSE) allowed patients to allow patients to report episodes of dysphagia in real-time, giving clinicians the ability to truly gauge the progress of the patient.

In an interview with HCPLive®, Evan S. Dellon, MD, MPH, Director of the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine, said it is easy for patients to lose track of the kind of progress they are making, so the self-reported diary does give a better frame of reference for past performance chewing and swallowing with EoE.

In the clinical trial, 26 patients were evaluated through 5 different waves in which patients labeled their dysphagia experience as uncomfortable and/or painful episodes that typically last less than 5 minutes.

The most common impacts were food avoidance and social impacts, where the patient avoided restaurants or social gatherings or bring their own food to places.

Patients reported PROSE provided a good assessment of their dysphagia experience.

Recent Videos
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.